🟢 Amneal Pharmaceuticals is trading 7.3% up today after beating Q2 estimates and raising guidance

Amneal Pharmaceuticals is trading at $20.49 (7.3% up) following a strong second-quarter earnings report and an improved financial outlook.

• Net revenue grew 10% year-over-year to $796 million, while adjusted EPS rose 20% to $0.30, surpassing analyst consensus estimates.
• Adjusted EBITDA increased 12% to $206 million, prompting management to raise its full-year 2026 revenue and EBITDA guidance.